In the BioHarmony Drug Report Database
Azilsartan kamedoxomil
Edarbi (azilsartan kamedoxomil) is a small molecule pharmaceutical. Azilsartan kamedoxomil was first approved as Edarbi on 2011-02-25. It is used to treat hypertension in the USA. It has been approved in Europe to treat hypertension. Edarbi’s patents are valid until 2028-03-26 (FDA).
Trade Name
|
Edarbi |
|---|---|
Common Name
|
azilsartan kamedoxomil |
ChEMBL ID
|
CHEMBL2103795 |
Indication
|
hypertension |
Drug Class
|
Angiotensin II receptor antagonists |
Image (chem structure or protein)